Kura Oncology Investor Relations Material
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company that develops medicines for the treatment of cancer in the United States. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications.
Key slides for Kura Oncology Inc
Lisa Su: Transforming AMD and Shaping the Semiconductor Industry
Explore Lisa Su's transformative leadership at AMD, including her role in revitalizing the company and her vision for semiconductor innovation.
26 Feb 2024
Klarna's Potential 2024 IPO: From Sequoia to Wall Street
Explore Klarna's journey from a 2005 startup to a fintech giant, its innovative business model, and the anticipation surrounding its 2024 IPO.
23 Feb 2024
Edward "Ted" Decker's Rise to the Top at Home Depot
Explore Ted Decker's transformative impact on Home Depot, including his leadership in retail innovation and strategic vision alongside Craig Menear.
15 Feb 2024
🇺🇸 United States